Guangzhou Baisailuo Pharmaceutical

Besino Pharmaceutical is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapies for chronic liver diseases and metabolic disorders. The company's primary focus is on addressing significant unmet medical needs in Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) and Chronic Hepatitis B (CHB). Its lead candidate, BES-001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently undergoing clinical evaluation for the treatment of NASH and dyslipidemia. Besino leverages its expertise in liver-targeted drug delivery and metabolic pathways to build a robust pipeline of candidates aimed at improving patient outcomes in global health priority areas.